Answers are grounded in this paper and cite their sources.
Metalloenzymes represent an important target space for drug discovery. A limitation to the early development of metalloenzyme inhibitors has been the lack of established structure–activity relationships (SARs) for molecules that bind the metal ion cofactor(s) of a metalloenzyme. Herein, we employed a bioinorganic perspective to develop an SAR for inhibition of the metalloenzyme influenza RNA polymerase PA N endonuclease. The identified trends highlight the importance of the electronics of the metal-binding pharmacophore (MBP), in addition to MBP sterics, for achieving improved inhibition and selectivity. By optimization of the MBPs for PA N endonuclease, a class of highly active and selective fragments was developed that displays IC 50 values <50 nM. This SAR led to structurally distinct molecules that also displayed IC 50 values of ∼10 nM, illustrating the utility of a metal-centric development campaign in generating highly active and selective metalloenzyme inhibitors.
No takes yet. Share an insight, caveat, or question.
Credille et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: